

# The Interplay between Anemia and Malaria Treatment Outcomes in East Africa: Implications for Clinical Recovery and Complication Risks

Bwanbale Geoffrey David

Faculty of Pharmacy Kampala International University Uganda

## ABSTRACT

Anemia is a common and often severe complication of malaria, especially in East Africa, where the dual burden of these conditions significantly contributes to morbidity and mortality. The complex interplay between malaria and anemia impedes clinical recovery, increases the risk of complications, and challenges the effectiveness of malaria treatment regimens. This review explores the pathophysiology of malaria-induced anemia, highlighting mechanisms such as hemolysis, impaired erythropoiesis, and nutritional deficiencies. The impact of anemia on malaria treatment outcomes is discussed, including delayed recovery, increased risk of multi-organ dysfunction, and reduced efficacy of antimalarial therapies. Special populations, such as children under five, pregnant women, and individuals with hemoglobinopathies, face heightened risks. The review emphasizes the need for integrated management strategies, including early anemia detection, tailored antimalarial treatments, and targeted nutritional interventions, to improve treatment outcomes in anemic malaria patients. Additionally, the review identifies critical research gaps and outlines future directions for enhancing malaria and anemia management, with a focus on cost-effective interventions and the development of comprehensive treatment protocols. Addressing both malaria and anemia simultaneously offers a promising approach to reducing disease burden and improving recovery rates in East Africa.

**Keywords:** Malaria, Anemia, East Africa, Treatment Outcomes, *Plasmodium falciparum*.

## INTRODUCTION

Malaria remains one of the most significant public health concerns in Africa, contributing substantially to morbidity and mortality rates in the region [1]. The disease is primarily caused by *Plasmodium* parasites, with *Plasmodium falciparum* being the most virulent and widespread species in East Africa [2]. Transmission occurs through the bite of infected female *Anopheles* mosquitoes, and despite concerted global and regional efforts to control malaria, the disease continues to pose a major challenge, particularly among vulnerable populations such as children under the age of five and pregnant women [3, 4]. Anemia is a frequent complication in malaria-endemic regions and significantly contributes to disease severity and adverse health outcomes [5]. The relationship between malaria and anemia is complex and multifaceted. Malaria contributes to anemia through mechanisms such as hemolysis (destruction of red blood cells), suppression of erythropoiesis (red blood cell production), and

increased splenic sequestration of infected and uninfected erythrocytes [6]. On the other hand, anemia itself affects immune function, reducing the body's ability to mount an effective response against malaria parasites, thereby complicating recovery and treatment outcomes [7]. Despite the well-documented link between malaria and anemia, there remains a significant gap in understanding the bidirectional impact of these conditions on disease progression, treatment efficacy, and long-term health consequences [8]. Additionally, interventions targeting malaria-related anemia often focus on singular approaches, such as iron supplementation or antimalarial treatment, without adequately considering their combined effects. Given the high prevalence of both malaria and anemia in East Africa, a more comprehensive understanding of their interaction is necessary to improve treatment protocols, enhance recovery rates, and reduce disease burden in affected populations [9]. Malaria-induced

anemia remains a critical but often overlooked health challenge in East Africa. While malaria control efforts have primarily focused on vector control strategies such as insecticide-treated bed nets, indoor residual spraying, and antimalarial drug distribution, anemia management has not received commensurate attention [10]. Many existing malaria treatment protocols do not adequately address the underlying anemia, which can prolong recovery time and increase the risk of complications such as severe fatigue, cognitive impairment, and, in extreme cases, heart failure [11]. Moreover, there is a lack of standardized guidelines for managing anemia in malaria patients, leading to inconsistencies in treatment approaches across different healthcare settings [12]. Many patients receive iron supplementation without adequate screening for underlying causes of anemia, such as nutritional deficiencies or hemoglobinopathies, which may further complicate malaria treatment [13]. Furthermore, pregnant women and children, who are most susceptible to malaria-related anemia, often face barriers in accessing timely and appropriate healthcare services, exacerbating disease outcomes [14, 15]. Given these challenges, there is a pressing need to examine the pathophysiology of malaria-induced anemia, its impact on treatment outcomes, and the potential interventions that can improve clinical recovery. This review seeks to bridge existing knowledge gaps by synthesizing current research findings and proposing integrated strategies for managing malaria and anemia in East Africa. This review aims to examine the pathophysiology of anemia in malaria, assess its impact on treatment outcomes, and explore potential interventions for improving clinical recovery in malaria-endemic regions of East Africa. The review will address key research questions such as the primary mechanisms by which malaria contributes to anemia in affected individuals, how anemia alters the

#### **Pathophysiology of Anemia in Malaria**

Anemia in malaria is a complex condition caused by multiple mechanisms, including direct parasite invasion, immune-mediated hemolysis, bone marrow suppression, and nutritional deficiencies [7]. The primary cause is the destruction of red blood cells (RBCs) through direct parasite invasion and immune-mediated mechanisms. *Plasmodium* species, particularly *Plasmodium falciparum*, invade RBCs, replicate inside them, and rupture the cells during schizogony, leading to anemia. This destruction results in the release of hemoglobin, leading to hemoglobinuria and potential complications such as blackwater fever. The immune system targets both infected and uninfected RBCs, activating macrophages in response to parasitic infection, leading to increased clearance of RBCs through phagocytosis [20]. Autoantibodies and complement

immune response and affects malaria treatment outcomes, existing interventions for managing malaria-related anemia, and potential integrated strategies for improving clinical recovery and reducing the burden of malaria-related anemia in East Africa. Understanding the intricate relationship between malaria and anemia is crucial for developing more effective treatment strategies and improving patient outcomes in malaria-endemic regions [16]. The findings hold significant implications for healthcare practitioners, policymakers, researchers, and public health organizations. Healthcare practitioners can adopt more comprehensive treatment approaches that address both conditions simultaneously, enhancing patient recovery rates and reducing disease complications [17]. Policymakers can highlight gaps in existing malaria and anemia treatment policies and provide evidence-based recommendations for improving healthcare guidelines. Researchers can build upon these findings to develop innovative treatment strategies, conduct clinical trials, and explore new therapeutic approaches for managing malaria-related anemia [18]. Public health organizations can leverage the findings to design targeted programs that address both malaria and anemia more effectively, including community-based interventions, educational campaigns, and improved healthcare access for vulnerable populations. Affected communities can raise awareness about the bidirectional impact of malaria and anemia, empowering them to seek timely medical attention, adhere to treatment protocols, and adopt preventive measures that reduce the risk of both conditions [19]. This review concludes that malaria-related anemia remains a significant yet underexplored health challenge in East Africa, necessitating a multidisciplinary approach that integrates malaria treatment with anemia management.

activation can further accelerate RBC destruction. Malaria can impair erythropoiesis, the production of new RBCs in the bone marrow, further exacerbating anemia. The malaria parasite induces dyserythropoiesis, suppressing RBC production despite increased demand. Inflammatory cytokines such as TNF- $\alpha$  and IL-6 are also triggered by malaria infection, suppressing erythropoietin production and causing apoptosis in bone marrow erythroid precursors. Nutritional deficiencies can result from chronic or recurrent malaria infection, impairing RBC synthesis and exacerbate anemia. Iron deficiency is caused by increased hepcidin production, which inhibits iron absorption and sequestration, and reduced iron availability limits hemoglobin synthesis [21]. Blood loss due to repeated hemolysis further depletes iron stores. Folate deficiency is caused by the

rapid turnover of RBCs in malaria infection, which impairs RBC maturation and worsens anemia. Coexisting malnutrition in endemic regions exacerbates folate deficiency, making individuals

### **Impact of Anemia on Malaria Treatment Outcomes**

Anemia significantly impacts malaria treatment outcomes by delaying clinical recovery, increasing the risk of severe complications, and reducing the effectiveness of antimalarial therapies [23]. The combined effects of reduced oxygen transport, prolonged parasite clearance, and altered drug metabolism contribute to poorer prognosis, especially in vulnerable populations such as children and pregnant women. Delayed clinical recovery is due to reduced hemoglobin levels and oxygen transport, which can lead to post-treatment fatigue, weakness, and cognitive impairment. This can impact daily activities, school performance, and economic productivity in affected adults. Prolonged parasite clearance, especially when coupled with malnutrition, weakens the immune response, leading to slower parasite clearance and increased risk of treatment failure, recrudescence, and drug resistance [24].

Severe anemia exacerbates cerebral hypoxia, a condition where oxygen supply to the brain is compromised, increasing the likelihood of neurological complications such as seizures, cognitive

### **Anemia and Malaria in Special Populations**

Certain populations, including children under five, pregnant women, and individuals with hemoglobinopathies, are disproportionately affected by the dual burden of anemia and malaria, leading to higher morbidity and mortality rates. Children under five in malaria-endemic regions often suffer from recurrent infections due to immature immunity, leading to persistent anemia and increased susceptibility to severe disease [3]. Chronic anemia impairs cognitive function, memory, and attention, leading to developmental delays, poor school performance, and long-term deficits in learning abilities. Pregnant women are more susceptible to malaria due to pregnancy-induced immunological changes, leading to reduced hemoglobin levels and exacerbating anemia. Severe anemia during pregnancy increases the risk of maternal mortality, postpartum hemorrhage, and infections [27]. Adverse birth outcomes include reduced oxygen delivery to the fetus, increased risk of low birth

### **Strategies for Improving Malaria Treatment Outcomes in Anemic Patients**

Addressing malaria in anemic patients requires a comprehensive approach that includes early detection, optimized treatment, nutritional interventions, healthcare system strengthening, and community-based prevention strategies [29]. These measures help reduce malaria-related complications, improve treatment efficacy, and enhance overall patient outcomes. Integrated Malaria and Anemia

more susceptible to severe anemia. Understanding these mechanisms is crucial for developing targeted interventions to prevent and manage malaria-associated anemia [22].

impairment, and coma in cases of cerebral malaria. Chronic or repeated episodes of malaria-related anemia may contribute to developmental delays and long-term neurocognitive deficits in children [25]. Multi-organ dysfunction is another issue, as severe anemia places additional stress on vital organs like the kidneys and liver, which are already vulnerable during malaria infection. Hypoxia-induced tissue damage can worsen kidney dysfunction, leading to acute kidney injury (AKI), a known complication of severe malaria. Liver impairment due to malaria-related anemia can result in jaundice, impaired drug metabolism, and further systemic complications [26]. Poor response to antimalarial medications is also a concern, as reduced red blood cell mass alters the pharmacokinetics of Artemisinin-Based Combination Therapies (ACTs), potentially leading to suboptimal drug concentrations and lower treatment efficacy. Drug-induced hemolysis, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, can lead to severe complications, requiring blood transfusions and prolonged hospitalization.

weight and intrauterine growth restriction (IUGR), and higher likelihood of preterm delivery and stillbirth. Placental malaria is associated with neonatal anemia, increasing infant morbidity and mortality. Patients with hemoglobinopathies, such as sickle cell disease and thalassemia, experience increased hemolysis, making malaria-induced anemia more severe [28]. Heterozygous carriers of sickle cell trait have partial protection against severe malaria, while homozygous individuals face worse outcomes. Malaria infections in patients with hemoglobinopathies often lead to vaso-occlusive crises, organ damage, and increased mortality. Targeting interventions such as intermittent preventive treatment in pregnancy (IPTp), iron and folate supplementation, early malaria diagnosis, and tailored drug regimens is essential to mitigate risks and improve health outcomes in these high-risk groups.

Screening Programs include routine hemoglobin and iron level assessments to identify high-risk patients and guide clinical decisions, especially in severe malaria cases requiring blood transfusion. Rapid diagnostic tests (RDTs) for malaria and portable hemoglobin meters enhance early diagnosis in rural and resource-limited settings [29-32]. Optimizing Antimalarial Treatment in Anemic Patients involves

tailored drug doses, minimizing drug-induced hemolysis, and implementing alternative treatment regimens for patients at risk. Nutritional and supplementation interventions include targeted iron and folic acid supplementation, food fortification programs, strengthening healthcare systems, expanding access to blood transfusion services, and public health campaigns on malaria and anemia awareness. Training healthcare workers on malaria-anemia interactions is crucial for early recognition and management of anemia in malaria patients [30-34]. Expanding access to blood transfusion services and establishing rural blood banks and transfusion centers in malaria-endemic areas can improve survival rates among critically ill malaria patients. Community-based malaria prevention strategies

### Future Directions and Research Gaps

Malaria-induced anemia remains a significant complication, especially in endemic regions, despite advancements in malaria treatment. Addressing key research gaps and exploring future directions will enhance our understanding and improve patient outcomes. The following areas require further investigation.

1. Longitudinal Studies on Malaria-Induced Anemia: Assess the long-term health effects of malaria-induced anemia, particularly in recurrent infections. Key Research Areas: Cognitive and developmental impacts of repeated malaria-associated anemia in children, recovery patterns post-malaria treatment, and long-term immune system alterations in previously infected individuals.
2. Development of Anemia-Specific Malaria Treatment Guidelines: Establish evidence-based protocols for managing malaria in anemic patients. Key Research Areas: Optimal antimalarial drug regimens, guidelines for iron and folate supplementation during malaria treatment, and transfusion thresholds for severe malaria anemia cases

The relationship between anemia and malaria treatment in East Africa is a significant challenge that requires a more integrated approach to healthcare management. Anemia, especially when induced by malaria, exacerbates disease severity, impairs immune function, and complicates recovery, especially in vulnerable populations. Current interventions often treat these conditions in isolation, overlooking their combined impact on patient outcomes. A more comprehensive approach is needed, integrating anemia screening with malaria diagnosis and treatment, involving tailored antimalarial therapies, nutritional supplementation, and community-based

include insecticide-treated bed nets (ITNs), intermittent preventive treatment (IPT) for pregnant women and children, and large-scale health education initiatives [30-34]. Public health campaigns on malaria and anemia awareness promote early malaria diagnosis, proper nutrition, and anemia prevention strategies. Improving malaria treatment outcomes in anemic patients requires a comprehensive and integrated approach that includes early screening, tailored treatments, nutritional support, enhanced healthcare infrastructure, and effective community-based prevention strategies. By addressing both malaria and anemia simultaneously, these interventions help reduce mortality, improve recovery rates, and enhance overall public health in endemic regions [1].

3. Genetic Studies on Malaria and Hemoglobin Disorders: Explore genetic predisposition to malaria-related anemia and its interaction with hemoglobinopathies. Key Research Areas: The role of sickle cell trait (HbAS) in modulating anemia severity in malaria patients, genetic markers influencing susceptibility to malaria-induced anemia, and interaction between thalassemia and malaria infection severity.
4. Cost-Effective Anemia Management Strategies in Malaria-Endemic Regions: Evaluate affordable and scalable interventions for managing anemia in malaria-endemic areas. Key Research Areas: Community-based iron supplementation programs, cost-effectiveness of food fortification, and sustainable blood transfusion models for rural settings.

Future research should focus on long-term health impacts, personalized treatment guidelines, genetic predisposition, and cost-effective interventions to improve malaria and anemia management. Addressing these research gaps will contribute to better clinical outcomes and sustainable public health strategies in malaria-endemic regions.

### CONCLUSION

prevention strategies. Strengthening healthcare infrastructure, including expanding access to blood transfusion services and improving healthcare worker training, will be crucial in addressing the dual burden of malaria and anemia. Research should focus on long-term effects of malaria-induced anemia, developing anemia-specific malaria treatment guidelines, genetic predispositions to anemia, and cost-effectiveness of interventions in resource-limited settings. A holistic approach targeting both conditions will lead to better clinical outcomes, quicker recovery, and reduced mortality, contributing

to the broader goal of reducing the public health burden of malaria and anemia in East Africa.

## REFERENCES

1. Egwu, C. O., Alope, C., Chukwu, J., Agwu, A., Alum, E., Tsamesidis, I, et al. A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. *Afr Health Sci.* 22(4):627-640(2022). doi: 10.4314/ahs.v22i4.68.
2. Zekar, L., Sharman, T.: *Plasmodium falciparum* Malaria. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
3. Alum, E. U., Tufail, T., Agu, P. C., Akinloye, D. I., & Obaroh, I. O. Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. *Medicine*, 103(49), e40241 (2024). doi: 10.1097/MD.00000000000040241. PMID: 39654176
4. Ekpono, E. U., Aja, P. M., Ibiam, U. A., Alum, E. U., & Ekpono, U. E. Ethanol Root-extract of *Sphenocentrum jollyanum* Restored Altered Haematological Markers in *Plasmodium berghei*-infected Mice. *Earthline Journal of Chemical Sciences.* 2(2): 189-203 (2019). <https://doi.org/10.34198/ejcs.2219.189203>.
5. Obeagu E I, Omar M N, Umi O. B, Ugwu O P C, Alum E U.(2023). Anaemia in children under five years: African perspectives. *Int. J. Curr. Res. Biol. Medicine* (1) 1-7 (2023).
6. Dumarchey, A., Lavazec, C., Verdier, F.: Erythropoiesis and Malaria, a Multifaceted Interplay. *International Journal of Molecular Sciences.* 23, 12762 (2022). <https://doi.org/10.3390/ijms232112762>
7. White, N.J.: Anaemia and malaria. *Malaria Journal.* 17, 371 (2018). <https://doi.org/10.1186/s12936-018-2509-9>
8. Starck, T., Bulstra, C.A., Tinto, H., Rouamba, T., Sie, A., Jaenisch, T., Bärnighausen, T.: The effect of malaria on haemoglobin concentrations: a nationally representative household fixed-effects study of 17,599 children under 5 years of age in Burkina Faso. *Malaria Journal.* 20, 416 (2021). <https://doi.org/10.1186/s12936-021-03948-z>
9. Immaculate N, Deogratius K, George W. N. (2013). Survey of *Brucella*infection and malaria among Abattoir workers in Kampala and Mbarara Districts, Uganda. *BMC public health*, 13, 1-6.
10. Kungu, E., Inyangat, R., Ugwu, O.P.C. and Alum, E. U. (2023). Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. *Newport International Journal Of Research In Medical Sciences* 4(1):101-108. [https://nijournals.org/wp-](https://nijournals.org/wp-content/uploads/2023/10/NIJRMS-41101-108-2023.docx.pdf)
11. Nkumama, I.N., O'Meara, W.P., Osier, F.H.A.: Changes in Malaria Epidemiology in Africa and New Challenges for Elimination. *Trends Parasitol.* 33, 128–140 (2017). <https://doi.org/10.1016/j.pt.2016.11.006>
12. Omarine Nlinwe, N., Nange, T.B.: Assessment of Hematological Parameters in Malaria, among Adult Patients Attending the Bamenda Regional Hospital. *Anemia.* 3814513 (2020). <https://doi.org/10.1155/2020/3814513>
13. Goheen, M.M., Wegmüller, R., Bah, A., Darboe, B., Danso, E., Affara, M., Gardner, D., Patel, J.C., Prentice, A.M., Cerami, C.: Anemia Offers Stronger Protection Than Sick Cell Trait Against the Erythrocytic Stage of *Falciparum* Malaria and This Protection Is Reversed by Iron Supplementation. *EBioMedicine.* 14, 123–130(2016). <https://doi.org/10.1016/j.ebiom.2016.11.011>
14. Bauserman, M., Conroy, A.L., North, K., Patterson, J., Bose, C., Meshnick, S.: An Overview of Malaria in Pregnancy. *Semin Perinatol.* 43, 282–290 (2019). <https://doi.org/10.1053/j.semperi.2019.03.018>
15. Mbishi, J.V., Chombo, S., Luoga, P., Omary, H.J., Paulo, H.A., Andrew, J., Addo, I.Y.: Malaria in under-five children: prevalence and multi-factor analysis of high-risk African countries. *BMC Public Health.* 24, 1687 (2024). <https://doi.org/10.1186/s12889-024-19206-1>
16. Crawley, J.: Reducing the Burden of Anemia in Infants and Young Children in Malaria-endemic Countries of Africa: From Evidence to Action. In: *The Intolerable Burden of Malaria II: What's New, What's Needed: Supplement to Volume 71(2) of the American Journal of Tropical Medicine and Hygiene.* American Society of Tropical Medicine and Hygiene (2004)
17. AbdulRaheem, Y.: Unveiling the Significance and Challenges of Integrating Prevention Levels in Healthcare Practice. *J Prim Care Community Health.* 14, 21501319231186500 (2023). <https://doi.org/10.1177/21501319231186500>
18. Alghamdi, J.M., Al-Qahtani, A.A., Alhamlan, F.S., Al-Qahtani, A.A.: Recent Advances in the Treatment of Malaria. *Pharmaceutics.* 16, 1416 (2024). <https://doi.org/10.3390/pharmaceutics16111416>



19. Baltzell, K., Harvard, K., Hanley, M., Gosling, R., Chen, I.: What is community engagement and how can it drive malaria elimination? Case studies and stakeholder interviews. *Malaria Journal*. 18, 245 (2019). <https://doi.org/10.1186/s12936-019-2878-8>
20. Ebele J I, Neboh E. E, Aguchime N. C, Maduka I C, Anyanwu E G.,(2010). Malaria parasitaemia: effect on serum sodium and potassium levels. *Biol Med*, 2, 2, 20-25.
21. Brittenham, G.M., Moir-Meyer, G., Abuga, K.M., Datta-Mitra, A., Cerami, C., Green, R., Pasricha, S.-R., Atkinson, S.H.: Biology of Anemia: A Public Health Perspective. *The Journal of Nutrition*. 153, S7-S28 (2023). <https://doi.org/10.1016/j.tjnut.2023.07.018>
22. Alum EU, Ugwu OPC, Egba SI, Uti DE, Alum BN. Climate Variability and Malaria Transmission: Unraveling the Complex Relationship. *INOSR Scientific Research*, 11(2):16-22 (2024). <https://doi.org/10.59298/INOSRSR/2024/1.1.21622>
23. Cusick, S.E., Opoka, R.O., Ssemata, A.S., Georgieff, M.K., John, C.C.: Delayed iron improves iron status without altering malaria risk in severe malarial anemia. *The American Journal of Clinical Nutrition*. 111, 1059-1067 (2020). <https://doi.org/10.1093/ajcn/nqaa004>
24. Nguyen, T.D., Gao, B., Amaratunga, C., Dhorda, M., Tran, T.N.-A., White, N.J., Dondorp, A.M., Boni, M.F., Aguas, R.: Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. *Nat Commun*. 14, 4568 (2023). <https://doi.org/10.1038/s41467-023-39914-3>
25. Ssemata, A.S., Nakitende, A.J., Kizito, S., Thomas, M.R., Islam, S., Bangirana, P., Nakasujja, N., Yang, Z., Yu, Y., Tran, T.M., John, C.C., McHenry, M.S.: Association of severe malaria with cognitive and behavioural outcomes in low- and middle-income countries: a meta-analysis and systematic review. *Malaria Journal*. 22, 227 (2023). <https://doi.org/10.1186/s12936-023-04653-9>
26. White, N.J.: Severe malaria. *Malaria Journal*. 21, 284 (2022). <https://doi.org/10.1186/s12936-022-04301-8>
27. Chua, C.L.L., Khoo, S.K.M., Ong, J.L.E., Ramireddi, G.K., Yeo, T.W., Teo, A.: Malaria in Pregnancy: From Placental Infection to Its Abnormal Development and Damage. *Front. Microbiol.* 12,(2021). <https://doi.org/10.3389/fmicb.2021.777343>
28. Olubunmi A, Faoziyat A. S, Abdulummeen A. H, Azeezat A, Abraham C A, Simbiat O, Basheer A B, Gabriel A. O, Learnmore K. In pursuit of new anti-malarial candidates: novel synthesized and characterized pyrano-benzodioxepin analogues attenuated *Plasmodium berghei* replication in malaria-infected mice. *Heliyon*, 7, (12), 8523 (2021). DOI:<https://doi.org/10.1016/j.heliyon.2021.e08517>
29. Emmanuel I. N., Ogonna C. A., Ugwu F J., Egba S. I., Aguzie I. O., Okeke O P., Dialoke C E., Asogwa L O., Odo S I. Malaria Prevalence in Rice Farm Settlements South East Nigeria. *IJTDH*, 41(9): 64-74 (2020).
30. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. *Research Invention Journal of Research in Medical Sciences*. 3(2):38-49 (2024).
31. Yusuf S. Enechi, O.C., Ugwu, Kenneth K., Ugwu Okechukwu P.C. and Omeh (2013). Evaluation of the antinutrient levels of *Ceiba pentandra* leaves. 3(3): 394-400.
32. Esther U Alum, Okechukwu PC Ugwu, Patrick M Aja, Emmanuel I Obeagu, Joseph E Inya, Amarachi P Onyeije, Esther Agu, Chinaza Godswill Awuchi (2023). Restorative effects of ethanolic leaf extract of *Datura stramonium* against methotrexate-induced hematological impairments. *Cogent Food & Agriculture*, 9(1): 2258774.
33. Emmanuel Ifeanyi Obeagu, Yahye Abdi Ahmed, Getrude Uzoma Obeagu, UO Bunu, OPC Ugwu, Esther U Alum (2023). Biomarkers of breast cancer: Overview. 8(1): 8-16.
34. Obeagu EI, EU Alum, OPC Ugwu (2023). The Gatekeeper of Iron in Malaria Resistance. *Newport International Journal of Research in Medical Sciences*, 4(2): 1-8.

**CITE AS: Bwanbale Geoffrey David (2025). The Interplay between Anemia and Malaria Treatment Outcomes in East Africa: Implications for Clinical Recovery and Complication Risks. IDOSR JOURNAL OF SCIENTIFIC RESEARCH 10(1):77-83. <https://doi.org/10.59298/IDOSRJSR/2024/10.1.7783>**